This trial is the first to address these issues by incorporating multiple unique additions to the study design including controlling for CINV-specific prognostic factors by recruiting only chemotherapy-nave patients , implementing a dosing schedule consistent with the pharmacokinetics of oral ginger supplements , and independently analysing ginger supplements before and after recruitment to ensure potency .